Please type a plus sign (+) inside this box + Approved for use through 10/31/2002. Of 2.051-0031,
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE for the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control to meet.

3

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

| Application Number | 08/648 |
|------------------------|-------------------------|
| Filing Date | May 17, 1996 |
| First Named Inventor | Johnston William McAvoy |
| Group Art Unit | 1614 |
| Examiner Name | Z. Fav |
| Attorney Docket Number | UNSYD-39709 |

| _ | | El | NCLOSURES | (check | all that apply) | |
|---|---------------------------------|--------------------|---|------------|---|--|
| Fee Transmittal For | m | | ssignment Papers or an Application) | | After Allowance Communication to Group | |
| Fee Attached | i | Dr | rawing(s) | | Appeal Communication to Board of Appeals and Interferences | |
| X Amendment / Reply | , | Lic | censing-related Papers | | Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) | |
| After Final | | | etition | | Proprietary Information | |
| Affidavits/de | claration(s) | Pr | etition to Convert to a rovisional Application | | Status Letter | |
| Extension of Time R | Request | | ower of Attorney, Revoca hange of Correspondence ddress | ition e | X Other Enclosure(s) (please identify below): | |
| Express Abandonm | ent Request | | erminal Disclaimer equest for Refund | | Postcard | |
| Information Disclose | _ c | D, Number of CD(s) | | | | |
| Certified Copy of Priority Document(s) | | Remarks | | | | |
| Response to Missing Parts/ Incomplete Application | | | | | | |
| Response to Missing Parts | | 24201 | | | | |
| under 37 CFR 1.52 or 1.53 | | | PATENT _TRADEMARK OFFICE | | | |
| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | | | | | | |
| Firm or Individual name | John V. Hanley, FULWIDER PATTON | | | | | |
| Signature | John V. Hay | | | | | |
| Date | January 26, 2001 | | | | | |
| | | | | | | |

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 1/26/2001 John V. Hanley Typed or printed name 1/26/2001 Signature Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:
Johnston William McAvoy
and Coral Gwenda Chamberlain

Serial No.: 08/648,092

Filed: May 17, 1996

Title: A METHOD FOR PREVENTING OR CONTROLLING CATARACT

Date: January 26, 2001

Examiner: Z. Fay

Group Art Unit: 1614

Certificate of Mailing Under 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on January 26, 2001.

John V. Hanley, Reg. No. 38, 71

RESPONSE TO FINAL OFFICE ACTION

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

On November 8, 2000, a final Office action was issued wherein pending claims 14-28 and 34-38 were rejected under 35 U.S.C. §103 as being unpatentable over Nagamoto and WO 91/04748. In rejecting the claims, the Examiner stated that the cited references teach the use of growth factor inhibitors in preventing fibrotic disease. In particular, the Examiner relied upon Nagamoto as teaching that "growth factor causes the fibrosis disorders such as secondary cataract." Moreover, it was stated in the outstanding Office action that "one skilled in the art would have been motivated to employ the teachings of the above references, since one relates to the effect of the inhibitors of the growth factor in treating fibrosis diseases and the other relates to the secondary cataract as a fibrotic disease."

#27 219/01 Serial No.: 08/648,092 **PATENT**

It is respectfully submitted, however, that the Nagamoto reference relied upon in the outstanding Office action, namely Nagamoto et al., "Alfa Smooth Muscle Actin Expression in Cultured Lens Epithelial Cells," <u>Investigative Opthamology & Visual Science</u>, April 2000, Vol. 41, No. 5, pages 1122-1129, is not prior art to the present application. In fact, since the Nagamoto reference was published in about April 2000, it bears a date that is well after the priority date of the claims of the present application. Moreover, it is to be recognized that a copy of the Nagamoto reference was submitted to the USPTO as part of a response to the March 20, 2000 Office action for the purpose of providing an example of a published reference which uses the term "after cataract" or "after-cataract." To wit, a copy of the reference was filed in order to demonstrate to the Examiner that the meaning of the term "after cataract" or "after-cataract" would be clear to one of ordinary skill in the relevant field.

Accordingly, it is respectfully submitted that the §103 rejection of pending claims 14-28 and 34-38 set forth in the November 8, 2000 Office action should be withdrawn.

Respectfully submitted,

FULWIDER PATTON LEE & UTECHT, LLP

Registration No. 38,171

JVH:kst Howard Hughes Center 6060 Center Drive, Tenth Floor Los Angeles, CA 90045 Tel. No.: (310) 824-5555

Facsimile: (310) 824-9696